Results 61 to 70 of about 28,815 (254)

Fine-mapping and molecular characterisation of primary sclerosing cholangitis genetic risk loci

open access: yesNature Communications
Genome-wide association studies of primary sclerosing cholangitis have identified 23 susceptibility loci. The majority of these loci reside in non-coding regions of the genome and are thought to exert their effect by perturbing the regulation of nearby ...
Elizabeth C. Goode   +10 more
doaj   +1 more source

Evaluation of the effectiveness of treatment of primary sclerosing cholangitis and autoimmune sclerosing cholangitis in children and adolescents

open access: yesMedičnì Perspektivi
Primary sclerosing cholangitis and autoimmune sclerosing cholangitis in children are rare chronic liver diseases characterized by progressive bile duct damage, fibrogenesis, and a risk of developing biliary cirrhosis. Autoimmune sclerosing cholangitis is
M.B. Dyba   +3 more
doaj   +1 more source

Oral vancomycin solution is superior to capsule in inducing clinical biomarker and endoscopic remission in children with atypical ulcerative colitis

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Atypical colitis (presenting reverse gradient colitis, backwash ileitis or rectal sparing) is associated with primary sclerosing cholangitis–ulcerative colitis (PSC). Oral vancomycin has been used to manage paediatric atypical colitis with/without confirmed PSC. Different preparations had shown different efficacy.
Laura Räisänen   +4 more
wiley   +1 more source

Secondary Sclerosing Cholangitis and Hodgkin's Lymphoma

open access: yes, 2015
Context Liver damage is relatively common in patients affected by HL, but paraneoplastic cholestasis is an uncommon presenting symptom in HL. Case Report We report the case of a 38-year-old man who came to our hospital with jaundice, pruritis, nausea ...
Seyed Hassan Abedi   +4 more
core   +1 more source

Orthotopic liver transplantation for primary sclerosing cholangitis [PDF]

open access: yes, 1988
The incidence or diagnostic rate of sclerosing cholangitis is increasing. Because of the lack of effective medical or surgical therapy for patients with end-stage liver disease and sclerosing cholangitis, results with orthotopic liver transplantation ...
Todo, S   +9 more
core   +1 more source

From Inflammatory Bowel Disease to Cancer: Gut Microbiota–Immune Microenvironment Crosstalk and Natural Product‐Based Therapeutic Opportunities

open access: yesCancer Nexus, EarlyView.
ABSTRACT Inflammatory bowel disease (IBD), primarily Crohn's disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract and an important risk factor for IBD‐associated cancer. Increasing evidence suggests that gut microbiota dysbiosis, epithelial barrier dysfunction, and immune microenvironment remodeling
Xue Zhang   +4 more
wiley   +1 more source

Clinical Features, Differential Diagnosis and Treatment of IgG4-Related Sclerosing Cholangitis

open access: yesАрхивъ внутренней медицины
The aim: To present the state-of-the-art of clinical features, differential diagnosis and treatment of IgG4-related sclerosing cholangitis.Key points: IgG4-sclerosing cholangitis is a fibrotic inflammatory disease affecting the intrahepatic and ...
A. K. Guseva, A. V. Okhlobystin
doaj   +1 more source

A Gentleman with Anemia and Cholestasis

open access: yesCase Reports in Medicine, 2010
Primary sclerosing cholangitis is a rare cause of cholestasis caused by progressive inflammation and fibrosis of both intrahepatic and extrahepatic bile ducts leading to multifocal ductal strictures.
Siu-Tong Law   +3 more
doaj   +1 more source

Sump syndrome of the remnant common bile duct following a living donor liver transplant

open access: yesJournal of Community Hospital Internal Medicine Perspectives, 2021
Sump syndrome – a collection of digested food, debris, stones, bile, and bacteria in a poorly drained, bile duct reservoir – occurs most commonly after a side-to-side choledochoduodenostomy.
Gordon Robbins   +5 more
doaj   +1 more source

Atezolizumab-induced Sclerosing Cholangitis in a patient with lung cancer: A case report

open access: yesCancer Treatment and Research Communications, 2021
Atezolizumab is an immune checkpoint inhibitor that is a key drug in non-small-cell lung cancer treatment. However, it can cause immune-related adverse events, including liver injury.
Shinji Nabeshima   +8 more
doaj   +1 more source

Home - About - Disclaimer - Privacy